EMA Procedural guidance for variant strain(s) update to vaccines intended for protection against Human coronavirus

June 24, 2022

8 June 2022
EMA/175959/2021 Rev.2
Human Medicines Division

Regulatory and procedural requirements

Introduction

In order to ensure the continued effectiveness of authorised COVID-19 vaccines, it may be necessary to modify the authorised human coronavirus vaccines composition so as to protect against new or multiple variant strain(s). Such changes, which include the replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences, should be considered as variations to the marketing authorisation in accordance to the Commission Regulation (EC) No 1234/2008 as amended by Commission Delegated Regulation (EU) 2021/756, provided the technological platform of the vaccine remains similar. The same approach should be followed for all human coronaviruses as set out in the Commission Delegated Regulation (EU) 2021/756. This guideline lays down the procedural aspects related to the submission of a variation to change the composition of a marketing authorisation for COVID-19 vaccines in the centralised procedure.

Download Procedural Guidance

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




EMA Europe

June 24, 2022

EMA Checklist for annual updates for parallel distribution - Draft Guidance

22/06/2022 EMA/405782/2020 Rev. 3 Human Medicines Division The European Medicines Agency (hereinafter 'the Agency') asks its applicants to use this checklist in advance of submission of an annual...

Read More
EMA Europe

June 24, 2022

EMA: List of centrally authorised products requiring a notification of a change for update of annexes

August 2022 EMA Regulatory and Procedural Guideline Parallel distributors are only required to inform the EMA of changes to the labelling or leaflet related to any update of the annexes of marketing...

Read More
EMA Europe

June 24, 2022

Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans - in relation to implementing measures under Article 37(5) of Regulation

Regulatory and Procedural Guideline May 2022 EMA/CVMP/678496/2021-rev Introduction “According to Article 37(5) of Regulation (EU) 2019/6 (‘the Regulation’), the European Commission shall adopt...

Read More